Evidence map›Paper›PMID 30191097›Full record

ArticlePreventive medicine reports2018

A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk.

Karianne Svendsen, Vibeke H Telle-Hansen, Lisa T Mørch-Reiersen, Kjersti W Garstad, Kari Thyholt, Linda Granlund, Hege Berg Henriksen, Jon Michael Gran, David R Jacobs, Kjetil Retterstøl

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Preventive medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02223793 (Effects of Cardiovascular Risk Screening in Pharmacies), which is not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02223793 naunknown statusnot on this map

Effects of Cardiovascular Risk Screening in Pharmacies: A Randomized Study

TypeinterventionalSponsorUniversity of OsloRan2014 to 2022Enrolled582ConditionsCardiovascular Diseases, Hypercholesterolemia, Dyslipidemia, Hypertensive DiseaseArmsInformation on high risk factor levels and lifestyle advice, No information on high risk factor levels but lifestyle advice, No information on high risk factor levels, nor lifestyle advice
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Karianne SvendsenDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317 Oslo, Norway.
Vibeke H Telle-HansenMills AS, P.O. Box 4644 Sofienberg, 0506 Oslo, Norway.
Lisa T Mørch-ReiersenBoots Norge AS, Maridalsveien 300, 0872 Oslo, Norway.
Kjersti W GarstadBoots Norge AS, Maridalsveien 300, 0872 Oslo, Norway.
Kari ThyholtMills AS, P.O. Box 4644 Sofienberg, 0506 Oslo, Norway.
Linda GranlundMills AS, P.O. Box 4644 Sofienberg, 0506 Oslo, Norway.
Hege Berg HenriksenDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317 Oslo, Norway.
Jon Michael GranOslo Centre for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Norway.
David R JacobsDivison of Epidemiology & Community Health, School of Public Health, University of Minnesota, 1300 S. 2nd Street, Minneapolis 55455, MN, United States.
Kjetil RetterstølDepartment of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317 Oslo, Norway.
Mills (Norway) · NOOslo University Hospital · NOUniversity of Oslo · NOUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated if alerting subjects to elevated total cholesterol (TC), hemoglobin A1c (HbA1c) and blood pressure (BP) (cardiovascular disease (CVD) risk factors that are usually asymptomatic), and if providing advice would result in reduced risk. We conducted a multicenter (50 community pharmacies) parallel three-arm 8-week randomized controlled trial (RCT) with a 52-week follow-up visit. During six days of screening, TC, HDL- and LDL-cholesterol, triglycerides, HbA1c, BP and body mass index (BMI) were assessed in 1318 individuals. Of these, 582 with a measured and predefined elevated ad hoc CVD risk score were randomized to either Alert/advice (n = 198) (immediately alerted of their screening result and received healthy lifestyle-advice), Advice-only (n = 185) (received only advice) or Control (n = 199) (not alert, no advice). Changes in risk score and self-reported health-related behaviors (diet, alcohol, physical activity) were assessed in pharmacies after 8 weeks (N = 543; 93%). Although the primary analysis showed no significant difference between groups, the Control group had the largest reduction in risk score of 14%. The total (uncontrolled) sample (N = 543) reduced the risk score by 3.2% beyond estimated regression towards the mean and improved their health-related behaviors. Among the 65% (n = 377) who returned 52 weeks after baseline, 14% reported started using CVD preventive medication after the screening. The study demonstrated that while assessing risk factors and behaviors in pharmacies proved efficient and possibly led to a small risk decrease, alerting people to their screening result did not seem to be more effective than a self-directed approach. ClinicalTrials.gov identifier: NCT02223793.

Identifiers

PMID30191097
PMCPMC6125803
OpenAlexW2887613501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.